PRESS RELEASE : MorphoSys and Incyte Announce -2-

because lenalidomide can cause birth defects and death of your unborn baby. 
- You should use an effective method of birth control (contraception) during treatment and for at least 3 months after 
your final dose of MONJUVI. 
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment 
with MONJUVI. 
- Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed 
during treatment for at least 3 months after your last dose of MONJUVI. 
You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and 
blood and sperm donation. 
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter 
medicines, vitamins, and herbal supplements. 
Please see the full Prescribing Information for Monjuvi, including Patient Information, for additional Important Safety 
Information. 
About MorphoSys 
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development 
and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its 
leading expertise in antibody, protein and peptide technologies, MorphoSys is advancing its own pipeline of new drug 
candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 
2017, Tremfya^(R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, 
Inc., for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive 
regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the 
company's proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a 
certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. 
subsidiary MorphoSys US Inc., has more than 600 employees. More information at www.morphosys.com or 
www.morphosys-us.com. 
Monjuvi^(R) is a registered trademark of MorphoSys AG. 
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc. 
About Incyte 
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet 
medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional 
information on Incyte, please visit Incyte.com and follow @Incyte. 
MorphoSys Forward-looking Statements 
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including 
the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell 
lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional 
interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional 
approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," 
"estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" 
and similar expressions are intended to identify forward-looking statements, although not all forward-looking 
statements contain these identifying words. The forward-looking statements contained herein represent the judgment of 
MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the 
actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be 
materially different from any historic or future results, financial conditions and liquidity, performance or 
achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, 
performance, financial condition and liquidity, and the development of the industry in which it operates are consistent 
with such forward-looking statements, they may not be predictive of results or developments in future periods. Among 
the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the 
impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, 
including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical 
supply of current or future drug candidates, commercial supply of current or future approved products, and launching, 
marketing and selling current or future approved products, the global collaboration and license agreement for 
tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' 
ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, 
additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible 
additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on 
collaborations with third parties, estimating the commercial potential of its development programs and other risks 
indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. 
Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on 
such forward-looking statements. These forward-looking statements speak only as of the date of publication of this 
document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document 
to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on 
which any such statement is based or that may affect the likelihood that actual results will differ from those set 
forth in the forward-looking statements, unless specifically required by law or regulation. 
Incyte Forward-looking Statements 
Except for the historical information set forth herein, the matters set forth in this press release, including 
statements regarding the Company's expectations regarding the use of tafasitamab for treatment of adult patients with 
relapsed or refractory diffuse large B-cell lymphoma (DLBCL), its ongoing clinical development program for tafasitamab, 
its L-MIND program, its diffuse large B-cell lymphoma (DLBCL) program generally and its further discussions with 
regulators regarding tafasitamab as a treatment for patients with DLBCL or for any other indication, contain 
predictions, estimates and other forward-looking statements. 
These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties 
that may cause actual results to differ materially, including unanticipated developments in and risks related to: 
unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful 
or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll 
sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned 
schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company's clinical trials, 
supply chain, and other third-party providers and development and discovery operations; determinations made by the FDA, 
European Medicines Agency (EMA), or other regulatory authorities; the Company's dependence on its relationships with 
its collaboration partners; the efficacy or safety of the Company's products and the products of the Company's 
collaboration partners; the acceptance of the Company's products and the products of the Company's collaboration 
partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and 
other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, 
including its annual report and its quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company 
disclaims any intent or obligation to update these forward-looking statements. 
^*Dr. Salles has provided speaking and advisory services to MorphoSys and Incyte. 
 
Contacts: 
MorphoSys 
Media Contacts:                                               Investor Contacts: 
Thomas Biegi                                                  Dr. Julia Neugebauer 
Vice President                                                Senior Director 
Tel.: +49 (0)89 / 89927 26079                                 Tel: +49 (0)89 / 899 27 179 
[e-mail]                                    [e-mail] 
Jeanette Bressi                                               Myles Clouston 
Director, U.S. Communications                                 Senior Director 
Tel: [phone]                                          Tel: [phone] 
[e-mail]                                 [e-mail] 
Incyte 
Media Contacts:                           Investor Contact: 
Catalina Loveman                          Christine Chiou 
Executive Director, Public Affairs        Senior Director, Investor   Relations 
Tel: [phone]                      Tel: [phone] 
[e-mail]                       [e-mail] 
Jenifer Antonacci 
Senior Director, Public Affairs 
Tel: [phone] 
[e-mail] 

(MORE TO FOLLOW) Dow Jones Newswires

June 04, 2021 13:33 ET (17:33 GMT)